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Purpose: The fixed-dose dual bronchodilator combination (FDC) of tiotropium and olodaterol 
showed increased effectiveness regarding lung function and health-related quality of life in 
patients with chronic obstructive pulmonary disease (COPD) compared with the use of its 
mono-components. Yet, while effectiveness and safety have been shown, the health economic 
implication of this treatment is still unknown. The aim of this study was to assess the cost–
utility and budget impact of tiotropium–olodaterol FDC in patients with moderate to very severe 
COPD in the Netherlands.
Patients and methods: A cost–utility study was performed, using an individual-level Markov 
model. To populate the model, individual patient-level data (age, height, sex, COPD duration, 
baseline forced expiratory volume in 1 second) were obtained from the tiotropium–olodaterol 
TOnado trial. In the model, forced expiratory volume in 1 second and patient-level data were 
extrapolated to utility and survival, and treatment with tiotropium–olodaterol FDC was com-
pared with tiotropium. Cost–utility analysis was performed from the Dutch health care payer’s 
perspective using a 15-year time horizon in the base-case analysis. The standard Dutch discount 
rates were applied (costs: 4.0%; effects: 1.5%). Both univariate and probabilistic sensitivity 
analyses were performed. Budget impact was annually assessed over a 5-year time horizon, 
taking into account different levels of medication adherence.
Results: As a result of cost increases, combined with quality-adjusted life-year (QALY) gains, 
results showed that tiotropium–olodaterol FDC had an incremental cost-effectiveness ratio 
of €7,004/QALY. Without discounting, the incremental cost-effectiveness ratio was €5,981/
QALY. Results were robust in univariate and probabilistic sensitivity analyses. Budget impact 
was estimated at €4.3 million over 5 years assuming 100% medication adherence. Scenarios 
with 40%, 60%, and 80% adherence resulted in lower 5-year incremental cost increases of €1.7, 
€2.6, and €3.4 million, respectively.
Conclusion: Tiotropium–olodaterol FDC can be considered a cost-effective treatment under 
current Dutch cost-effectiveness thresholds.
Keywords: COPD, cost-effectiveness, health economics, cost–utility, budget impact
Introduction
The Global initiative for chronic Obstructive Lung Disease (GOLD) defines chronic 
obstructive pulmonary disease (COPD) as a common preventable and treatable disease, 
characterized by persistent airflow limitation that is usually progressive and associated 
with enhanced chronic inflammatory airway response to noxious particles or gases.1 
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Exacerbations and comorbidities contribute to the overall 
severity of COPD. COPD has been projected to become the 
third largest cause of death by 2030, after cancer and car-
diovascular disease.2 While smoking is widely recognized 
as the major risk factor for COPD, especially in developing 
countries, biomass smoke and indoor cooking result in an 
increasing prevalence of COPD.3
Besides nonpharmacologic treatments, several effective 
pharmacologic inhaled therapies for COPD are available. 
The main drug class to reduce symptoms and future risk in 
moderate to very severe COPD is the class of long-acting 
bronchodilators, that is, long-acting beta-agonists (LABA) 
and long-acting muscarinic antagonists (LAMA). In patients 
not sufficiently controlled with a single bronchodilator, a 
second bronchodilator of a different class may be added 
according to the GOLD guidelines. There seems a pharmaco-
logic rationale for combining two classes of bronchodilators4 
and some studies indeed showed the added value compared 
with the use of a single bronchodilator,5 but full synergistic 
effects have not been observed.
In addition to bronchodilators, inhaled corticosteroids 
(ICS) have been commonly used, often in a fixed-dose 
combination (FDC) with a bronchodilator. Although ICS 
are considered the cornerstone pharmacologic treatment in 
asthma patients, the use of ICS in patients with COPD is 
more controversial.6 ICS can have both systemic and local 
side effects7,8 and there seems limited added clinical value 
as compared with bronchodilators.9 Recently, the WISDOM 
study showed that ICS could be stepped down safely, that 
is, without increased exacerbation risk, as long as dual bron-
chodilators were continued.10
Spiolto Respimat® is a once-daily dual bronchodilator 
consisting of the FDC of the LAMA tiotropium and the 
LABA olodaterol delivered through the Respimat® Soft Mist 
inhaler. Tiotropium has been used for over a decade and is 
among the most commonly used therapies for patients with 
COPD. The effectiveness, safety, and cost-effectiveness of 
tiotropium have been evaluated in several large randomized 
controlled trials such as the UPLIFT and the POET.11–13 Due 
to its recent market introduction, so far only few studies have 
been performed with olodaterol; however, initial results seem 
beneficial with regard to its efficacy,14,15 and its safety profile 
is comparable with existing LABAs.1
Recently, the FDC of tiotropium and olodaterol showed 
increased effectiveness regarding lung function, physical 
functioning, and health-related quality of life compared with 
the use of its mono-components.16–18 Yet, while effectiveness 
and safety have been shown, the cost-effectiveness of the 
new FDC is still unknown. In times of an increasing burden 
of chronic diseases on governmental health care budgets, 
there is an obvious need for economic evaluation of newly 
available treatments. Therefore, the aim of this study was to 
assess the cost-effectiveness of tiotropium–olodaterol FDC 
in patients with moderate to very severe COPD.
Materials and methods
study design
A cost–utility analysis was performed, using an individual-
level Markov model. A cost–utility analysis is a special type 
of cost-effectiveness analysis that uses the quality-adjusted 
life-year (QALY) as outcome measure.
Type of model
A deterministic individual-level Markov model was used in 
which patients were tracked over time rather than placed in 
fixed health states (such as GOLD 1, 2, 3, and 4). To popu-
late the model, individual patient-level data (age, height, 
sex, COPD duration, baseline forced expiratory volume in 
1 second value [FEV
1
]) were obtained from the tiotropium–
olodaterol clinical TOnado trial.16 As patient’s lung function 
declines, increased mortality risk, management costs, and 
exacerbation risk are seen, while quality of life decreases. 
These phenomena form the basis of the individual-based 
Markov model.19
Note that an advantage of the current model from typi-
cal cohort models is that it is not “memory-less”, a common 
feature of Markov models in which the risk of future events 
is not affected by what has occurred in previous cycles. For 
example, the risk of exacerbation in future cycles increases 
based on the incidence of an exacerbation in the previous 
year, in line with observations in clinical studies.20
Perspective
The cost–utility analysis was performed from the Dutch 
health care payer’s perspective. Applying a health care 
payer’s perspective implicates that only direct medical costs, 
such as medication, hospitalization, and primary care visits, 
were included. Indirect costs, such as work productivity 
losses,21 were neglected as differences in these costs were not 
measured. In addition, as the vast majority of COPD patients 
were older than the legal retirement age, the relative contribu-
tion of these costs seems limited in this population.
Comparison
In the Markov model, treatment with tiotropium–olodaterol 
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Cost-effectiveness of tiotropium–olodaterol in the netherlands
Tiotropium is one of the most widely used drugs for COPD 
and is considered a suitable comparator to represent usual care 
in the Netherlands.22 In addition, tiotropium has been used as 
comparator in a previous economic study that evaluated the 
cost-effectiveness of another FDC LABA–LAMA.23
Cycle length
The cycle length of the model was 1 month in order to 
minimize the probability of patients experiencing multiple 
exacerbations in a given cycle and to fully capture the impact 
of exacerbations on costs and outcomes. Using a longer 
cycle length would not allow modeling of those patients 
who may suffer from exacerbations in consecutive months, 
which could be the case for COPD patients with the frequent 
exacerbator phenotype.20 Shorter than 1-month cycle lengths 
would not be necessary in the current model as it is unlikely 
that a patient would experience more than one moderate 
or severe exacerbation within this time frame.24 The cycle 
length was 1 month, however, the cycles through 52 weeks 
corresponded to the clinical trial visits and ranged from 2 to 
12 weeks in duration.16
Time horizon
The time horizon of the analysis was 15 years. As COPD is a 
chronic condition and according to the Dutch pharmacoeco-
nomics guidelines, the model allowed patients to be followed 
over their lifetime, defined as a maximum period of 60 years, 
or a maximum age of 100 years given the minimum age of 
40 years in the tiotropium–olodaterol FDC clinical trial. 
A 5-year time horizon may be considered the most compa-
rable to published long-term trials in COPD considering that 
the studies providing clinical inputs (ie, lung function decline, 
exacerbation rates, mortality) all included follow-up times 
of ,5 years. However, given the mean age of 64 years in 
the trial,16 and the high rates of mortality in COPD patients 
compared with the general population, a 15-year time horizon 
was considered most appropriate.
Model assumptions
No adverse events related to treatment with bronchodilators 
were considered. This was justified given that side effects 
from bronchodilators are comparable across products and 
do not contribute significantly to either costs or outcomes 
of treatment. The model did not account for the possibility 
of differential rates of treatment switch. Differential add-on 
treatment and treatment discontinuation were not considered. 
All surviving patients died at an age of 100 years. These 
assumptions have been chosen as there is no indication 
from clinical trials that any of the available bronchodilator 
combinations differ in these aspects. Accounting for these 
aspects would therefore not directly bias the analysis in favor 
or against tiotropium–olodaterol FDC.
Model inputs
lung function decline
Following treatment initiation, improvement in FEV
1
 was 
tracked in clinical visits in the clinical trial up to 52 weeks 
for the assessment of tiotropium–olodaterol FDC versus 
tiotropium.16 Classification of patients according to sever-
ity level was done using postbronchodilator trough FEV
1
 
values so that patients were classified by their potential to 
achieve a given level of lung function. Patients were clas-
sified into GOLD stages based on FEV
1
 using the GOLD 
2007 criteria (GOLD stage II: 50%# FEV
1
 predicted ,80%, 
stage III: 30%# FEV
1
 predicted ,50%, stage IV: FEV
1
 
predicted ,30%) (Table S1).
After the trial period of 52 weeks, a constant linear decline 
in FEV
1
 was applied over time, not differentiated by treat-
ment, but by the GOLD severity stage. As of its long-term 
follow-up (4 years), the rates of decline by severity stage 
observed in the tiotropium arm of the UPLIFT trial are cur-
rently used in the model, with greater declines in the less 
severe stages (Table S2). These differential rates of decline 
obtained from the UPLIFT trial25 are consistent with the find-
ings of a review that concluded that lung function decline is 
more prominent earlier in the disease.26 Given that UPLIFT 
is one of the longest recent clinical trials on tiotropium in 
COPD, with published rates of decline that vary by GOLD 
stage, this was chosen as the best data source of lung func-
tion decline.25 The study was exempted from IRB approval 
because of the use of anonymized data. Written informed 
consent was also therefore not sought.
exacerbation risk
Exacerbation risk in the base case was estimated based on a 
random-effects logistic regression analysis of patient-level 
data of exacerbations from the 4-year UPLIFT trial compar-
ing treatment with tiotropium to placebo. Using data from 
the tiotropium treatment group only, the risks regarding the 
dichotomous outcomes of moderate exacerbation (nonsevere) 
and hospitalization due to severe exacerbation within a month 
were estimated. The explanatory variables in the regression 
analyses (Tables S3 and S4) included exacerbations in pre-
vious year, FEV
1
% predicted, hospitalizations in previous 
year, and patients’ age in months. There was no direct effect 
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However, exacerbation was indirectly influenced as a result 
of improved lung function in the tiotropium–olodaterol FDC 
arm in the first 52 weeks, compared with tiotropium.16
Mortality
Patients faced a mortality risk in every cycle in the model 
and the exact risk was calculated as a function of COPD 
severity stage. Excess mortality due to COPD was obtained 
by comparing mortality with GOLD stage in the clinical trial 
versus the general population mortality adjusted by age and 
sex. The mortality rate applied in each cycle was obtained 
from two sources. The first source was a study of a large 
cohort of COPD patients in which mortality was a primary 
outcome that was used to estimate the excess mortality in 
COPD patients.27,28
Mortality in the general population by age and sex was 
obtained from the Dutch Bureau of Statistics. Mortality 
risk was not impacted by the incidence of exacerbations 
given that it would be double counting the risk. Previous 
published models used similar approaches to calculate mor-
tality, differing mainly in the data source used to obtain the 
mortality risk.29
Utilities
In order to reflect the impaired quality of life in patients with 
COPD, utility weights were assigned independently to each 
disease state, and to each exacerbation event. 
In the base case, previously published utility values were 
used.30 Utility weights by disease state (Table S2) had been 
derived from a representative subset of patients enrolled in 
the UPLIFT trial.
Consistent with previous cost-effectiveness models of 
bronchodilator treatment in COPD, patients experienced 
a temporary decrement in utility during an exacerbation, 
lasting the duration of one cycle before returning to their 
previous utility level, assigned by severity stage.31 The 
magnitude of the utility decrement varied by whether the 
patient experienced a severe or nonsevere exacerbation. 
The utility decrement multipliers for each type of exacer-
bation obtained from the published literature were applied 
in the same way regardless of which data source for base-
line utility values was used. Utility decrements following 
nonsevere and severe exacerbation were 0.85 and 0.50, 
respectively.32,33
Costs
Since the perspective adopted for the base-case analysis 
was that of the Dutch health care payer, the model reflected 
direct medical expenditures associated with bronchodilator 
therapy and other COPD treatments. All health care costs 
were expressed in 2014 Euros. An overview of the costs is 
provided in Table 1.
Discounting
For costs occurring after 1 year, a discount rate of 4% 
was applied in line with the Dutch guidelines. For effects 
occurring after 1 year, a discount rate of 1.5% was applied 
in line with the Dutch guidelines.34
Outcomes
Clinical outcomes included life years, exacerbation free 
months per patient per year, annual nonsevere exacerba-
tions, and annual severe exacerbations. In addition, an 
incremental cost-effectiveness ratio (ICER) was calculated 
with the formula Δcosts/Δeffects, with effects expressed as 
QALYs gained.
Model validation
The model has been used in a previous study and has been 
compared with existing COPD models.19 In addition, the 
model has been validated against results from the TOnado 
trial. It was found that total exacerbations were similar to 
the numbers observed in the trial, while modeled mortality 
was slightly higher.19
sensitivity analyses
Both univariate and probabilistic sensitivity analyses were 
conducted.
Univariate sensitivity analysis allows the investigator to 
determine the impact of uncertainty around one model input 
on the cost-effectiveness results, while probabilistic analysis 
is conducted by taking values from statistical distributions 
Table 1 Cost parameters
Parameter Value (€, 2014) Source
Medication per pack







gOlD 2 712.42 hettle et al52
gOlD 3 1,494.83 hettle et al52
gOlD 4 2,468.59 hettle et al52
Exacerbations
nonsevere 177.35 hettle et al52
severe 5,600.19 hettle et al52
Abbreviations: COPD, chronic obstructive pulmonary disease; FDC, fixed-dose 
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Cost-effectiveness of tiotropium–olodaterol in the netherlands
(often based on confidence intervals or fixed deviations 
from the best estimate) for several parameters at the same 
time. When confidence intervals were not specified in a 
given data source, it was by authors’ consensus decided to 
modify inputs relating to costs and utilities by ±15%, in line 
with a previous COPD cost-effectiveness study.35
The probabilistic sensitivity analysis (PSA) was based on 
a Monte Carlo simulation, where the model was run a large 
number of times (ie, 100 times) with different sets of inputs 
simulated according to statistical distributions (Table S5) that 
were assigned for all parameters, surrounded by uncertainty 
likely to have a significant impact on the cost-effectiveness 
results. The choice of statistical distribution used for each 
parameter included in the PSA was based on published 
recommendations for economic evaluation in health care.36
For each simulation, inputs were randomly selected from 
their statistical distributions, and pairs of data points for costs 
and effectiveness for each treatment were obtained. At the 
end of the simulation process, the joint statistical distribu-
tion for costs and effectiveness was represented as a cloud 
of points on a cost-effectiveness plane. Cost-effectiveness 
acceptability curves were generated, representing the prob-
ability of each treatment being the most cost-effective for a 
range of cost-effectiveness thresholds.
Budget impact
analytical framework
In a linked model, budget impact was assessed using a 
COPD patient-level model approach in Microsoft Excel. 
A Dutch health care payer’s perspective was adopted. 
Treatment-specific lung function improvements after 2 weeks 
were applied to baseline FEV
1
 distributions as found in the 
Netherlands and tracked over 5 years assuming a fixed 30 mL 
annual decline. Calculations were performed for an incident 
and a prevalent cohort, including only direct health care costs 
(Table 1). Given that health insurance bodies work with 
yearly budgets, budget impact was calculated per year with 
a maximum time horizon of 5 years. All inputs and assump-
tions were similar to the cost-effectiveness model. Costs 
are provided in their undiscounted form and no mortality 
was assumed.
size of the eligible population
The COPD incidence and prevalence were based on the 
Dutch national data sources.37 The GOLD distributions for 
the incident38 and prevalent39 COPD population were based 
on the Dutch and, in case of absent Dutch data, international 
population estimates.
Current mix of treatments and 
alternative scenarios
Medication distributions over 5 years were based on the 
manufacturer’s projections of market share within a group of 
(combined) bronchodilators, including tiotropium, indacaterol–
glycopyrronium, umeclidinium–vilanterol, aclidinium–
formoterol, tiotropium–salmeterol (separate inhalers), 
vilanterol–fluticasone furoate (Table S6). Scenarios with and 
without tiotropium–olodaterol FDC over 1, 2, 3, 4, and 5 years, 
respectively were compared. Costs of these treatments were 
based on the Dutch costs prices (www.medicijnkosten.nl).
Uncertainty and scenario analyses
To account for lower medication uptake as seen in real-life 
practice, shown in the Dutch national adherence monitor,40 
scenarios with different extents of medication adherence 
were assessed, including scenarios with 40%, 60%, 80%, 
and 100% medication adherence.
Results
Cost-effectiveness
Base-case analyses, using our best estimates for each input 
variable, were performed first. In Table 2, the per-patient 
results of the base-case cost-effectiveness analysis are shown, 
based on the 15-year time horizon. Patients on tiotropium–
olodaterol FDC gained 8.38 QALYs at an expense of 
€32,423. Patients on tiotropium gained 8.31 QALYs at an 
expense of €31,989.
Taking into account discounting over this 15-year time 
horizon, an ICER of €7,004/QALY results; without discount-
ing the ICER is €5,981/QALY.
In Table 3, the clinical outcomes are shown. Over a 
15-year time horizon, treatment with tiotropium–olodaterol 
FDC resulted in slightly better clinical outcomes including 
life-years gained and prevented exacerbations of all types. 
Annually, treatment with tiotropium–olodaterol FDC resulted 
in the prevention of 0.035 exacerbations (0.03 severe and 
0.006 nonsevere) per patient.
sensitivity analyses
In Table 4, univariate sensitivity analyses are shown for 
extreme values of the model. Results seem robust in several 
sensitivity analyses.
In Figure 1, the PSA is shown. Treatment with tiotropium–
olodaterol, as well as tiotropium alone, resulted in both cost 
increases and QALY gains, although differences were mar-
ginal. Additionally, a cost-effectiveness acceptability curve 
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Tiotropium–olodaterol FDC €32,423 €25,002 8.3787 7.6231
Tiotropium €31,989 €24,494 8.3062 7.5506
Difference €434 €508 0.0725 0.0726
Abbreviations: FDC, fixed-dose combination; QALYs, quality-adjusted life-years.
Table 3 Clinical outcomes






















Tiotropium–olodaterol 11.184 11.21 5.337 3.185 0.477 0.285 0.762
Tiotropium 11.127 11.17 5.370 3.502 0.483 0.315 0.797
Difference 0.057 0.040 −0.033 −0.317 −0.006 −0.030 −0.035
As shown, tiotropium–olodaterol FDC is cost-effective 
at the lowest – so far – suggested Dutch cost-effectiveness 
threshold of €20,000.41 The probability of being cost-effective 
at that threshold is 61.4%. The probability would slightly 
increase to 65.3% at higher thresholds such as at €30,000,22 
but remains stable despite higher thresholds.
Budget impact
In Figure 3, the total yearly national Dutch costs of COPD 
treatment over a time horizon up to 5 years is presented for 
a scenario without (left part of each column) and with (right 
part of each column) tiotropium–olodaterol, assuming 60% 
medication adherence. Mainly due to expected rise in number 
of COPD patients, total COPD costs are increasing from 
€489.1 million without tiotropium–olodaterol (€489.2 with) 
in 2015 to €663.2 without tiotropium–olodaterol (€664.1 
with) million in 2019. As shown, introducing tiotropium–
olodaterol will be responsible for less than 1% of the total 
increase in COPD expenses.
In Figure 4, the incremental budget impact of introducing 
tiotropium–olodaterol FDC over a time horizon of 5 years is 
presented. Due to expected rise in number of COPD patients 
and increased market share projections (ranging from 0.6% 
of COPD patients that require long-acting bronchodilators 
on tiotropium–olodaterol in year 1 to 7.7% in year 5, see 
Table S4), incremental costs are increasing from €55,288 
in 2015 to €877,641 in 2019 (summing up to €2.6 million 
over 5 years).
Scenarios with 40%, 80%, and 100% medication adher-
ence resulted in lower or higher 5-year incremental cost 
increases of €1.7, €3.4, and €4.3 million, respectively.
Discussion
As a result of cost increases, combined with QALY gains, 
results showed that tiotropium–olodaterol FDC had an ICER 
of €7,004 per QALY. Without discounting, the ICER was 
€5,981 per QALY. Results were robust in univariate and 
probabilistic sensitivity analyses. Budget impact was esti-
mated at €2.6 million over 5 years, assuming 60% adherence. 
Scenarios with 40%, 80%, and 100% adherence resulted in 
lower or higher 5-year incremental cost increases of €1.7, 
€3.4, and €4.3 million, respectively.
In a previous study, the cost-effectiveness of the 
mono-component tiotropium was favorable.12 In addition, 
a more recent economic evaluation of another fixed-dose 
LABA–LAMA (umeclidinium–vilanterol), with tiotropium 
as comparator, concluded that the new treatment was consid-
ered cost-effective in the Spanish setting with an estimated 
ICER of €21,475.22 This ICER was higher than in our study, 
but note that a shorter time horizon of 3 years was used 
and indeed shorter time horizons may not capture the full 
economic benefits, as shown in our sensitivity analyses. 
In a cost-effectiveness analysis of another dual bronchodi-
lator, indacaterol–glycopyrronium FDC was not compared 
with tiotropium, but with both its mono-components and 
with salmeterol–fluticasone, and was found cost-saving in 
the Swedish health care setting.42 Yet, due to the choice of 
these different comparators, which may not be considered 
usual care, and the inclusion of pneumonia as side effect of 
ICS use, results are not directly comparable to our study.
In 2007, the Dutch report of the National Institute of 
Public Health (RIVM)43 reported that €415 million was 
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Cost-effectiveness of tiotropium–olodaterol in the netherlands
Table 4 sensitivity analyses
Variable Mean (min; max) ICER (min) ICER (max)
Base case All mean values €6,930 €6,930
COPD-related mortality (RR)
age ,60 years, gOlD 2 1.73 (1.47; 1.98) €4,673 €5,422
age 60–69 years, gOlD 2 1.42 (1.20; 1.63)
age $70 years, gOlD 2 1.09 (0.92; 1.25)
age ,60 years, gOlD 3 5.69 (4.83; 6.54)
age 60–69 years, gOlD 3 2.20 (1.87; 2.53)
age $70 years, gOlD 3 1.42 (1.21; 1.63)
age ,60 years, gOlD 4 15.52 (13.19; 17.85)
age 60–69 years, gOlD 4 4.72 (4.01; 5.43)
age $70 years, gOlD 4 2.99 (2.55; 3.44)
Lung function decline (mL)
gOlD 2 37.10 (31.54; 42.67) €8,126 €2,536
gOlD 3 30.70 (26.10; 35.31)
gOlD 4 24.20 (20.57; 27.83)
Exacerbation risk
risk nonsevere exacerbation see supplementary materials €10,975 €8,415
risk severe exacerbation see supplementary materials Dominant €13,150
Costs
Management gOlD 2 (monthly) €59 (50; 68) €7,522 €6,485
Management gOlD 3 (monthly) €125 (106; 143)
Management gOlD 4 (monthly) €206 (175; 237)
nonsevere exacerbations €177 (152; 204) €6,984 €7,024
severe exacerbations €5,600 (4,760; 6,440) €8,832 €5,175
Utilities
gOlD 2 0.787 (0.771; 0.802) €4,080 €4,984
gOlD 3 0.750 (0.731; 0.768)
gOlD 4 0.647 (0.598; 0.695)
nonsevere exacerbation (multiplier) 0.85 (0.72; 0.98) €7,045 €6,963
severe exacerbation (multiplier) 0.50 (0.43; 0.57) €6,912 €7,098
Discount rate
Cost and QALYs 0%; 5% €5,981 €7,365
Time horizon
52 weeks – €37,425
5 years – €6,784
10 years – €7,840
lifetime – €11,464
Abbreviations: COPD, chronic obstructive pulmonary disease; gOlD, global initiative for chronic Obstructive lung Disease; ICer, incremental cost-effectiveness ratio; 
QALY, quality-adjusted life-year; RR, relative risk; min, minimum; max, maximum.
Figure 1 Probabilistic sensitivity analysis (100 iterations).
Abbreviations: QALYs, quality-adjusted life-year; Tio, Tiotropium; Olo, Olodaterol.
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Figure 2 Cost-effectiveness acceptability curves.































Figure 3 Total Dutch COPD health care costs with and without tiotropium–
olodaterol FDC (in million euros).
Notes: Blue: medication, green: management, orange: exacerbations.
Abbreviations: COPD, chronic obstructive pulmonary disease; FDC, fixed-dose 
dual bronchodilator combination.
The estimated total burden of COPD in our model was 
€550 million in 2014 and 28% comprised medication. 
Hence, our burden estimate was slightly higher, while the part 
due to medication was somewhat lower. Differences in total 
expenses are likely due to methodological differences and the 
year of calculation. Indeed, the RIVM expects an increase in 
number of COPD patients from about 350,000 currently to 
600,000 in 2032 and then our expenses are in line with future 
projections.43 In addition, RIVM calculations were based 
on prescription data, while up to 10%–15% of respiratory 
medication was actually never dispensed.44 Notably, when 
real-world medication adherence measures were applied in 
our study, medication expenses were considerably lower. The 
assumption of 60% adherence is well in line with adherence 
reported in Dutch national data over the period 2007–2014 
(60%–64%),40 confirming the validity of our base-case budget 
impact assumption on adherence.
This is the first full economic evaluation of tiotropium–
olodaterol FDC for the Netherlands. It is based on the best 
currently available evidence, a validated model, and includes 
extensive uncertainty analyses. In addition, exacerbation risk, 
a main cost driver, was calculated using a real-life approach. 
While some previously published models in COPD have 
estimated the risk of both severe and moderate exacerbations 
by treatment as well as by GOLD stage,29,45 other economic 
evaluations have estimated overall exacerbation risk by 
treatment only46 or estimated the proportion of severe to 
nonsevere exacerbations by GOLD stage.47 These approaches 
have limitations in that the probability of exacerbations is 
not affected by having experienced a previous exacerba-
tion, while a history of exacerbations has been shown to 
be the most reliable predictor for future exacerbations.19,23 
Yet, some potential limitations have to be noted. In the cost-
effectiveness analyses, adverse events from bronchodilators 
were not incorporated, although these side effects are con-
sidered of only minor importance and likely to be equally 
prevalent among comparators. In addition, differential rates 
of treatment switch or add-on treatments were not considered; 
however, these were assumed equally plausible. The same 
goes for the extent of treatment discontinuation. Finally, 
relatively long-term projections of 15 years are naturally 
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<HDU <HDU <HDU <HDU
Based on current Dutch thresholds, the cost-effectiveness 
ratio of tiotropium–olodaterol FDC in the Netherlands is 
generally favorable. However, other factors than solely 
cost-effectiveness ratios may play a role in recommenda-
tions regarding reimbursement and implementation in 
clinical guidelines. From a clinical perspective, one should 
take into account that once-daily therapies are associated 
with increased adherence48,49 and that nonadherence to 
COPD medication is associated with decreased clinical and 
economic outcomes.50 Moreover, when two inhaled drugs 
are indicated, the use of a single inhaler is recommended in 
order to avoid confusion and inhalation technique errors.51 In 
choosing the optimal inhaler, patient’s needs and preferences 
should not be overlooked.
Regarding future research, it is recommended to assess the 
effectiveness and cost-effectiveness of tiotropium–olodaterol 
and other FDC LAMA–LABAs in real-life studies, including 
their effects on patient-reported outcomes.
Conclusion
Tiotropium–olodaterol FDC can be considered a cost-
effective treatment under currently suggested Dutch cost-
effectiveness thresholds.
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